According to loose sources Mori was a small Japanese study.. run in 2010..
The only study I saw authored by Mori was a study using EPA to treat IGA nephrophy (kidney disease)...It used only 18 patients and did not in any way deal with blood lipids..Closing remark was The effect of EPA in patients with IgA nephropathy is not pronounced, but these results suggest that EPA is a safe and worthwhile supplement to the drugs used to treat this disease.
I do not know if this is the Mori study and maybe someone on the board knows..I can say JELIS which was 18,000 patient study done in Japan was reviewed by the AHA (American Heart Association) who panned the study for its poor design...And though this suggested EPA could lower CVD event risk..But was largely ignored by the experts in the USA...
The fact I am unaware of the any other Mori means clinicians did not consider it opinion worthy. And I would say that was the case for any Japanese study in 2010...
Market Data 
Markets 
AI
